LLY vs NVO stock comparison
ELI LILLY & Co vs. Novo Nordisk A S · data as of November 13, 2026
ELI LILLY & Co (LLY) has a market value of about $1.36T, Novo Nordisk A S (NVO) about $184.3B. Over their latest twelve months ELI LILLY & Co had revenue of $86.5B and Novo Nordisk A S $49.2B.
Both score 3.4 out of 5 on our five checks.
By area, the stronger company is Novo Nordisk A S on value; ELI LILLY & Co on future growth; ELI LILLY & Co on shareholder returns.
Novo Nordisk A S is cheaper on earnings (P/E 11.1 vs. 46.9), while ELI LILLY & Co grew revenue faster over five years (21.6% vs. 18.4% a year).
ELI LILLY & Co leads on 7 of the compared lines and Novo Nordisk A S on 14.
Side by side
| LLY | NVO | |
|---|---|---|
| Size and price | ||
| Market cap | $1.36T | $184.3B |
| Share price | $1,443.50 | $41.63 |
| Score | ||
| Overall score (of 5) | 3.4 | 3.4 |
| Value | 0 | 3 |
| Future growth | 5 | 3 |
| Track record | 5 | 5 |
| Financial health | 3 | 3 |
| Shareholder returns | 4 | 3 |
| Valuation | ||
| P/E (TTM) | 46.9 | 11.1 |
| Forward P/E | 30.4 | 12.1 |
| Price / free cash flow | 69.1 | 27.8 |
| Price / sales | 15.7 | 3.7 |
| EV / EBITDA | 37.1 | 7.4 |
| PEG | 1.70 | 0.57 |
| DCF value vs. price | −37% | −37% |
| Business | ||
| Revenue | $86.5B | $49.2B |
| Net income | $27.6B | $16.7B |
| Free cash flow | $19.7B | $6.6B |
| Net margin | 31.9% | 33.9% |
| Gross margin (5-yr avg.) | 78.9% | 83.5% |
| ROIC (5-yr avg.) | 22.9% | 47.5% |
| Growth | ||
| Revenue growth (1 yr) | 44.7% | 20.2% |
| Revenue growth (5 yrs, per year) | 21.6% | 18.4% |
| EPS growth (5 yrs, per year) | 27.6% | 19.5% |
| Balance sheet and payouts | ||
| Net cash (cash minus debt) | -$44.6B | -$13.0B |
| Dividend yield | 0.48% | 4.32% |
| Shareholder yield | 0.8% | 4.4% |
| Analysts | ||
| Upside to average target | +1% | — |
| Consensus rating | Buy | Hold |
Highlighted = the better figure on that line. Revenue, net income and free cash flow: LLY TTM to September 30, 2026, NVO TTM to September 30, 2026. Not investment advice.
Frequently asked questions
Which is the better stock, ELI LILLY & Co or Novo Nordisk A S?
We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) ELI LILLY & Co scores 3.4 out of 5 and Novo Nordisk A S 3.4; the table shows where each one is stronger.
Is ELI LILLY & Co cheaper than Novo Nordisk A S?
On trailing earnings, Novo Nordisk A S trades at a P/E of 11.1 and ELI LILLY & Co at 46.9, so Novo Nordisk A S is cheaper by this measure. A lower P/E can also reflect slower expected growth.
Which grows faster, ELI LILLY & Co or Novo Nordisk A S?
Over five years ELI LILLY & Co grew revenue about 21.6% a year and Novo Nordisk A S about 18.4% a year.
Which pays a higher dividend?
ELI LILLY & Co yields 0.48% and Novo Nordisk A S 4.32%.
Full ELI LILLY & Co analysis → Full Novo Nordisk A S analysis →
More comparisons
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.